NCI Genome-Wide Association Study of Renal Cell Carcinoma

The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-control), scanned using the Illumina InfiniumHumanHap 550, 610 and 660W chips. This project was supported by the Intramural Research Program of the National Institutes of Health and NCI. Data from this GWAS were pooled with those from another GWAS of RCC (2,639 cases and 5,392 controls) conducted in Europe by the International Agency for Research on Cancer and the Centre National de Gènotypage. Findings from this collaboration are described in an upcoming report (Purdue et al. Nature Genetics 2011;43(1):60-65; PMID: 21131975). Only data from the NCI scan are included in this dbGaP submission.]]>
Renal GWAS Supplementary MethodsInclusion criteria: Non-Hispanic Caucasian race Adequate consent for GWAS Cases: diagnosis of pathologically confirmed renal cancer (International Classification of Diseases for Oncology, Second Edition, Topography C64). ]]>
Of the 4 studies participating in the NCI GWAS of RCC, 3 are prospective cohorts and 1 is a case-control study. The studies are: Cohorts: Alpha-Tocopherol and Beta-Carotene Cancer Prevention Study (ATBC) American Cancer Society Cancer Prevention Study-II (CPS-II) Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) Case-control: National Cancer Institute United States Kidney Cancer Study (USKC) ]]>